Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson’s Disease: Experience in Clinical Trials

BACKGROUND: Due to the short half-life of levodopa, immediate-release carbidopa-levodopa (IR CD-LD) produces fluctuating LD concentrations, contributing to a risk of eventual motor complications. IPX066 was designed to rapidly attain therapeutic LD concentrations and maintain them to allow a dosing...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Parkinsons Dis
Egile Nagusiak: Nausieda, Paul A., Hsu, Ann, Elmer, Lawrence, Gil, Ramon A., Spiegel, Joerg, Singer, Carlos, Khanna, Sarita, Rubens, Robert, Kell, Sherron, Modi, Nishit B., Gupta, Suneel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: IOS Press 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4927929/
https://ncbi.nlm.nih.gov/pubmed/26444090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-150622
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak